Study participants All study participants provided written informed consent at Spring House PA, Johnson & Johnson Innovative Medicine, US. The clinical protocol was approved by an institutional review board. PBMC processing methods Individual human blood was collected into VacutainerTM tubes containing sodium heparin anticoagulant (Becton Dickinson, #367874). PBMCs were isolated from blood samples using 50 mL SepMate™ tubes (STEMCELL, #85450).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Spring House
Corrigendum to “B7-H3 as a Therapeutic Target in Advanced Prostate Cancer” [European Urology 83 (2023) 224–238
|
By Christina Guo, Spring House, Ines Carreira Figueiredo, Inés Carnall Figueiredo, Inês Bravo Figueiredo, Bora Gurel, Antje Neeb, George Seed, Mateus Crespo, Suzanne Carreira, Jan Rekowski, Lorenzo Buroni, Jon C. Welti, Denisa Bogdan, Lewis Gallagher, Adam Sharp, Pasquale Rescigno, Daniel Westaby, Maria D. Fenor de la Maza
|
European Urology
Verified
The authors regret that post-publication, concerns were raised by a reader regarding this article (https://pubpeer.com/publications/2EAD25DB56BC0D75D911F9C63CB382).
Editorial: Advances in Therapeutic Cancer Vaccines: Mechanisms and Development
EDITORIAL article Volume 17 - 2026 | doi: 10.3389/fimmu.2026.1838269 EDITORIAL article MM Mariam Mathew George 1 CB Cory Brennick 2 JM James Moon 3 JL Jayon Lihm 4 HC Hyejin Choi 5 1. Weill Cornell Medicine, New York, United States 2. University of Connecticut School of Medicine, Farmington, United States 3. University of Michigan, Ann Arbor, United States 4. Memorial Sloan Kettering Cancer Center, New York, United States 5.
Machine learning-based proteogenomic data modeling identifies circulating plasma biomarkers for early detection of lung cancer
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10–45 (2025). Google Scholar Henderson, L. M., Rivera, M. P. & Basch, E. Broadened eligibility for lung cancer screening: challenges and uncertainty for implementation and equity. JAMA 325, 939–941 (2021). Google Scholar Kanwal, M., Ding, X.-J. & Cao, Y. Familial risk for lung cancer. Oncol. Lett. 13, 535–542 (2017). Google Scholar Lebrett, M. B. et al.
Leveraging machine learning to predict Parkinson's disease using pre-symptomatic proteomics data
In Parkinson’s disease, non-motor symptoms precede the characteristic motor manifestations by up to 20 years. However, predicting the disease risk remains challenging. We analyzed 2,937 plasma proteins assayed in UK Biobank participants with Parkinson’s disease, and applied machine learning (ML) to predict disease outcome up to 14 years before diagnosis. 446 proteins were dysregulated in incident cases compared to controls.
In vitro and in vivo characterization of wild type BMP9 and a non-osteogenic variant in models of pulmonary arterial hypertension
Loading metrics Open Access Peer-reviewed Research Article Citation: Schips TG, Kavalkovich KW, Yung L-m, Ibrahim S, Edmondson M, Hong Z, et al. (2025) In vitro and in vivo characterization of wild type BMP9 and a non-osteogenic variant in models of pulmonary arterial hypertension. PLoS One 20(7): e0329089.
A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease - Cardiovascular Diabetology
A study flow diagram for the CREDENCE study participants included in the present analysis is detailed in Supplemental Fig. 1. From a starting population of 2711 in the CREDENCE trial, there were 1117 study participants with sufficient follow up and complete data from which analyses were performed. Supplemental Table 1 details comparisons between baseline characteristics of those included versus those not included from the CREDENCE trial dataset.
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
aUniversity Hospital of Salamanca/IBSAL/Cancer Research Center–IBMCC (USAL-CSIC), Salamanca, Spain bCancer Center Clínica Universidad de Navarra, CCUN, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain cIRCCS Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy dDepartment of Hematology, Japanese...
Canagliflozin and iron metabolism in the CREDENCE trial
Studies in patients with heart failure have indicated that sodium-glucose cotransporter 2 (SGLT2) inhibitors increase iron use and enhance erythropoiesis. In this post-hoc analysis of the CREDENCE trial, we evaluated the effects of canagliflozin on iron metabolism in patients with chronic kidney disease (CKD) and whether the effects of canagliflozin on hemoglobin and cardiorenal outcomes were modified by iron deficiency.
An Easy Additive Approach for Replacing Fluorocarbon Surfactants
Manufacturers of waterborne coatings are encountering heightened regulatory demands to transition towards more eco-friendly formulations. These formulations must not only have low VOC levels, but also exclude substances of very high concern (SVHC) such as fluorocarbon surfactants (FCS) and alkyl phenol ethoxylates (APEs).
Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU
To assess the efficacy and safety of apalutamide plus goserelin for androgen receptor (AR)–positive unresectable or recurrent/metastatic salivary gland carcinoma. This trial was an open-label, single-arm, multicenter phase II study. Patients with histologically confirmed unresectable or recurrent/metastatic salivary gland carcinoma with AR expression were included.
The mode of action of IL-23 in experimental inflammatory arthritic pain and disease - Arthritis Research & Therapy
It has been reported by us using Il23p19−/− mice that the IL-23p19 subunit is required for the development of innate immune-driven, zymosan-induced inflammatory pain as well as zymosan-induced arthritic pain and disease [3]. In the current study, to explore the mechanisms governing this IL-23p19 subunit dependence, we aimed firstly to identify IL-23p19-expressing and IL-23-responding cells that could be important for zymosan-induced arthritis (ZIA) pain and disease.
Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD | NEJM
Affiliations 2Janssen Research and Development, Spring House, PA 3Janssen Research and Development, Raritan, NJ 4Janssen Research and Development, Spring House, PA 5Janssen Research and Development, Raritan, NJ 6Arrowhead Pharmaceuticals, Pasadena, CA 7Janssen Pharmaceutical, Tokyo, Japan 8Endeavor Clinical Trials, San Antonio, TX 9CenExel RCA, Hollywood, FL 10Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan 11Sumida Hospital, Tokyo, Japan 12OCROM Clinic, Osaka, Japan 13Medical Corporation...
Raman spectroscopy as an alternative rapid microbial bioburden test method for continuous, automated detection of contamination in biopharmaceutical drug substance manufacturing
To investigate an in-line Raman method capable of detecting accidental microbial contamination in pharmaceutical vessels, such as bioreactors producing monoclonal antibodies via cell culture. The Raman method consists of a multivariate model built from Raman spectra collected in-line during reduced-scale bioreactor batches producing a monoclonal antibody, as well as a reduced-scale process with intentional spiking of representative compendial method microorganisms (n = 4).
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer
As the second most common cause of cancer-related death in the United States, metastatic colorectal cancer (mCRC) is a prevalent and lethal disease.1 We saw a rapid expansion of the drug armamentarium for mCRC around the turn of the century with successive FDA approvals of irinotecan (1998), oxaliplatin (2004), bevacizumab (2004), and cetuximab (2004) that incrementally increased median survival from approximately 9 to 12 months to over 2 years.
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer
To read this article in full you will need to make a payment Subscribe to European Urology References Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 35: 3097-3104 ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era. Ann Oncol.
A new test for trait mean and variance detects unreported loci for blood-pressure variation
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Probing CRL4DCAF12 interactions with MAGEA3 and CCT5 di-Glu C-terminal degrons
DDB1- And CUL4- Associated Factor 12 (DCAF12) serves as the substrate recognition component within the Cullin4-RING E3 Ligase (CRL4) complex, capable of identifying C-terminal double-glutamic acid degrons to promote the degradation of specific substrates through the ubiquitin proteasome system. MAGEA3 and CCT5 proteins have been identified as cellular targets of DCAF12.
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis - Clinical Rheumatology
Abstract To evaluate the association between enthesitis resolution (ER) and dactylitis resolution (DR) and meaningful improvements in patient-reported outcomes (PROs) among biologic-naïve patients with PsA receiving guselkumab in the DISCOVER-2 study. Enthesitis and dactylitis, characteristic lesions of PsA, were evaluated by independent assessors using the Leeds Enthesitis Index (range, 0–6) and Dactylitis Severity Score (range, 0–60).
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus | Arthritis Research & Therapy | Full Text
The human donors (healthy controls and people with OA, arthralgia, UA, early RA and established RA) in this study have been described previously [18]. Briefly, synovial biopsy specimens from healthy and donors with OA were obtained from a group of patients attending a sports medicine facility with knee pain. Healthy subjects were defined as those who had no arthritis, cartilage damage or synovitis on knee arthroscopy.
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide; hepatocellular carcinoma (HCC) accounts for 75%-85% of such diagnoses.1 Early-stage HCC is amenable to locoregional treatments including surgical resection, radiofrequency ablation, transarterial chemoembolization (TACE), Y90 radioembolization, and liver transplantation.2,3 Traditionally, locoregional therapies such as Y90 radioembolization have been limited to intermediate stage...
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis
Previously published long-term safety data reported a favorable ustekinumab safety treatment profile for treatment of inflammatory bowel disease (IBD). We present the final cumulative safety data from pooled ustekinumab IBD phase 2/3 clinical studies through 5 years in Crohn’s disease (CD) and 4 years in ulcerative colitis (UC).
Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants - Molecular Neurodegeneration
References Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–30. Article CAS PubMed Google Scholar Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501–18. Article CAS PubMed PubMed Central Google Scholar Bu G. APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants. Mol Neurodegener.
Role of Glycosuria in SGLT2 Inhibitor-Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial
Avoiding glycosuria has been a mainstay in the management of diabetes, with the aim of preventing or reducing symptoms and monitoring metabolic control of the disease. However, over the past decade, the role of the kidney in diabetes has been revisited.
G protein-coupled receptors and obesity
Alessandro Pocai1* 1Johnson & Johnson Innovative Medicine, Cardiovascular and Metabolism, Janssen Research and Development (United States), United States The final, formatted version of the article will be published soon. Receive an email when it is updated G protein-coupled receptors (GPCRs) have emerged as important drug targets for various chronic diseases, including obesity and diabetes.
Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study | Arthritis Research & Therapy | Full Text
Arthritis Research & Therapy volume 25, Article number: 170 (2023) Cite this article The Original Article was published on 16 August 2023 Correction: Arthritis Res Ther 25, 150 (2023) https://doi.org/10.1186/s13075-023-03125-4 Following publication of the original article [1], the authors reported that the corrections were not carried out during the revisions. The corrections are provided below and the changes have been set in bold typeface.
Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat - BMC Genomics
The samples included in the analysis were pooled from three studies sponsored by Janssen Research & Development, LLC including 54861911ALZ2002 (NCT02260674), a Phase 2a study to evaluate the safety and tolerability of atabecestat (JNJ-54,861,911), an oral BACE1 inhibitor in participants with early Alzheimer’s Disease [17]; 54861911ALZ2004 (NCT02406027, terminated), the long-term extension study of (JNJ-54,861,911) in early Alzheimer’s disease spectrum patients [17]; and...
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study | Arthritis Research & Therapy | Full Text
The study design and participant eligibility criteria for COSMOS have been previously described [15].
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
Purpose: In this first-in-human, Phase 1, open-label, multicenter study, we evaluated JNJ-64619178, a selective and potent PRMT5 inhibitor, in patients with advanced malignant solid tumors or non-Hodgkin lymphomas. The primary objective was to evaluate the safety and to identify a recommended Phase 2 dose (RP2D) of JNJ-64619178.
Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike
Cryo-EM analysis of variant spikes To understand the structural impact of the large NTD deletions and the loss of DS15-136 (ΔDS15-136) in the ΔN135 variant, we solved the Cryo-EM structures of the stabilized ectodomains of both spike variants (Figs 5, S7, and S8 and S3 Table). The overall structures of the ΔN135 and ΔN25 trimers are the same as that of the Wuhan spike with the D614G mutation except for the loops in the NTD [40].
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE | Cardiovascular Diabetology | Full Text
Study populations CANVAS Program The CANVAS Program, which integrated the CANVAS and CANVAS-R trials, investigated the effects of canagliflozin on CV, renal and safety outcomes in 10,142 patients with T2D and either established CV disease or at high CV risk, with a mean follow-up time of 188 weeks. Details of the CANVAS Program design have been published [11, 12].
Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus infections
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure | British Journal of Dermatology | Oxford Academic
What is already known about this topic? • None Guselkumab is a fully human monoclonal antibody that binds and inhibits the p19 subunit of interleukin-23. • None Multiple phase II and III clinical trials have established favourable safety and efficacy profiles for guselkumab in patients with moderate-to-severe plaque psoriasis. What does this study add?
Re: Prostate Cancer Polygenic Risk Score and Prediction of Lethal Prostate Cancer
• None Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. : • None Prespecified 4 kallikrein marker model (4Kscore) at age 50 or 60 for early detection of lethal prostate cancer in a large population based cohort of asymptomatic men followed for 20 years. : • None Polygenic risk scores to stratify cancer screening should predict mortality not incidence.
Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis
DISCUSSION This study investigated the safety and efficacy of the MK2 pathway inhibitor ATI-450 in patients with moderate-to-severe RA. ATI-450, a mechanistically novel compound that targets the p38 MAPK/MK2 complex and selectively inhibits the proinflammatory MK2 pathway, was well tolerated in this study, although numbers of subjects were small.
Metabolism-based approaches for autosomal dominant polycystic kidney disease
Ivona Bakaj1 and Alessandro Pocai1* 1Janssen Research and Development (United States), United States Provisionally accepted: The final, formatted version of the article will be published soon. Autosomal Dominant Polycystic Kidney Disease (ADPKD) leads to end stage kidney disease (ESKD) through the development and expansion of multiple cysts throughout the kidney parenchyma.
A graph-based approach for the visualisation and analysis of bacterial pangenomes - BMC Bioinformatics
Early comparative genomic studies of bacteria revealed the extensive genetic variability between different isolates of the same species [1, 2]. As more genomes were sequenced and the true extent of genetic variation became apparent, the term ‘pangenome’ was coined to denote the full genetic repertoire of a group of isolates, typically defined at the species level [3].
Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
Table IDescriptive summary of studies. 6-MP = 6-mercaptopurine; AZA = azathioprine; CD = Crohn's disease; CRP = C-reactive protein; MTX = methotrexate; N = patients treated; PK = pharmacokinetic; q8w = administration every 8 weeks; q12w = administration every 12 weeks; TNF = tumor necrosis factor. Patients who did not respond to IV placebo induction therapy received SC ustekinumab 270 mg at week 8 and 90 mg at week 16. † Week 0 samples were obtained preadministration and 1 hour postinfusion.
Unlocking the Potential: A Systematic Review of Master Protocol in Pediatrics - Therapeutic Innovation & Regulatory Science
Abstract The use of master protocols allows for innovative approaches to clinical trial designs, potentially enabling new approaches to operations and analytics and creating value for patients and drug developers. Pediatric research has been conducted for many decades, but the use of novel designs such as master protocols in pediatric research is not well understood. This study aims to provide a systematic review on the utilization of master protocols in pediatric drug development.
Bicyclobutanes: from curiosities to versatile reagents and covalent warheads
Bicyclobutanes: from curiosities to versatile reagents and covalent warheads Christopher B. Kelly, *a John A. Milligan, *b Leon J. Tilley c and Taylor M. Sodano d Abstract The unique chemistry of small, strained carbocyclic systems has long captivated organic chemists from a theoretical and fundamental standpoint. A resurgence of interest in strained carbocyclic species has been prompted by their potential as bioisosteres, high fraction of sp3 carbons, and limited appearance in the patent literature.
Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study - The Patient - Patient-Centered Outcomes Research
Abstract Objective The Phase 3 DISCOVER-1 study of guselkumab is the first randomized controlled trial to use Patient-Reported Outcomes Measurement Information System (PROMIS) measures to assess the effects of treatment on general health outcomes in patients with psoriatic arthritis (PsA).
High risk of depression, anxiety, and an unfavorable complex comorbidity profile is associated with SLE: a nationwide patient-level study - Arthritis Research & Therapy
Data source De-identified records were obtained from the longitudinal, nationwide database of the Hungarian National Health Insurance Fund (NHIF).
The role of interleukin (IL)-23 in regulating pain in arthritis - Arthritis Research & Therapy
Arthritis Research & Therapy volume 24, Article number: 89 (2022) Cite this article Abstract Current understanding of IL-23 biology, with its link to other pro-inflammatory cytokines, for example, IL-17 and granulocyte macrophage-colony stimulating factor (GM-CSF), is primarily focused on T lymphocyte-mediated inflammation/autoimmunity. Pain is a significant symptom associated with many musculoskeletal conditions leading to functional impairment and poor quality of life.
Development and characterization of rabbit monoclonal antibodies that recognize human spermine oxidase and application to immunohistochemistry of human cancer tissues
Loading metrics Open Access Peer-reviewed Research Article Armand W. J. W. Tepper, Gerald Chu, Vincent N. A. Klaren, Jay H. Kalin, Patricia Molina-Ortiz, Antonietta Impagliazzo Armand W. J. W. Tepper, Gerald Chu, Vincent N. A. Klaren, Jay H. Kalin, Patricia Molina-Ortiz, Antonietta Impagliazzo Published: April 22, 2022 https://doi.org/10.1371/journal.pone.0267046 Abstract The enzyme spermine oxidase (SMOX) is involved in polyamine catabolism and converts spermine to spermidine.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Skip Nav Destination CLINICAL TRIALS AND OBSERVATIONS| January 27, 2022
PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells
Loading metrics Open Access Peer-reviewed Research Article Brian Rady , Takahiro Nishio , Debanjan Dhar, Xiao Liu, Mark Erion, Tatiana Kisseleva, David A. Brenner, Alessandro Pocai Brian Rady, Takahiro Nishio, Debanjan Dhar, Xiao Liu, Mark Erion, Tatiana Kisseleva, David A.
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
Skip Nav Destination Lymphoid Neoplasia| November 18, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
Key Points Question Are specific molecular features associated with benefit from the addition of apalutamide to androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer?
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Spring
Contact Spring, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack